廣州安必平醫(yī)藥科技股份有限公司位于廣州科學(xué)城，擁有醫(yī)學(xué)、生物學(xué)、分析化學(xué)、機(jī)械自動(dòng)化控制等跨學(xué)科的高級(jí)技術(shù)人員組成的研發(fā)團(tuán)隊(duì)，專注病理診斷產(chǎn)品的研發(fā)生產(chǎn)與服務(wù)。
公司自二OO五年成立至今，通過(guò)與衛(wèi)生部生物醫(yī)藥工程技術(shù)研究中心及中山大學(xué)等科研單位合作，歷年來(lái)承擔(dān)了國(guó)家科技部中小企業(yè)創(chuàng)新基金，國(guó)家高技術(shù)研究發(fā)展計(jì)劃(863計(jì)劃) 及各級(jí)政府的科研項(xiàng)目共8項(xiàng)，已取得各項(xiàng)專利11項(xiàng)，正在申報(bào)專利6項(xiàng)。獲得了高新技術(shù)企業(yè)認(rèn)定，軟件企業(yè)認(rèn)定和ISO13485認(rèn)定。
病理診斷從早期顯微鏡下的形態(tài)學(xué)診斷發(fā)展到的分子基因診斷，為當(dāng)今臨床醫(yī)學(xué)前沿的個(gè)性化診斷與個(gè)性化治療提供了條件，市場(chǎng)前景廣闊。安必平公司通過(guò)自主研發(fā)創(chuàng)新及與國(guó)際病理診斷領(lǐng)域的企業(yè)合作，形成了病理診斷試劑及配套設(shè)備全系列產(chǎn)品，包括液基細(xì)胞學(xué)、免疫組織化學(xué)和分子基因診斷。隨著中國(guó)醫(yī)藥集團(tuán)醫(yī)療健康投資管理有限責(zé)任公司和中山大學(xué)達(dá)安基因股份有限公司等的投資加盟，我們正努力把安必平公司建設(shè)成為我國(guó)醫(yī)學(xué)病理診斷行業(yè)的者。
我們相信：病理診斷推動(dòng)醫(yī)療進(jìn)步！ LBP Medicine Science & Technology Co., Ltdis located in Guangzhou Science City. It is a high-tech biomedical enterprise focusing on research & development. Its R & D team has senior interdisciplinary technical staffs, which is composed of medicine, biology, analytical chemistry and mechanical automation control. LBP Company focuses on R & D and production of the pathological diagnosis and services.
Since established at 2005, LBP has been in cooperation with the Biomedicine Engineering Research Center of the Ministry of Health, the Sun Yat-sen University and other research units, and over the years has been assumed a total of 8 projects, including the State Ministry of Science and Technology Innovation Fund for SMEs, the National High Technology Research and Development Program (863 Program) and all levels of government research projects. Until now, LBP has been obtained 11 patents , and are applying for 6 more patents. Moreover, LBP has passed the high-tech enterprises and the software companies and ISO13485 certification. diagnosis of Medicine in China industry leader.
From the early microscope morphological diagnosis to the molecular genetic diagnosis, nowadays, pathological diagnostic techniques has been provided the necessary conditions for a broad market prospect of clinical personalized diagnosis and treatment.
Depending on its independent research and innovation, and through cooperation with the international field of pathological diagnosis, LBP has already covered a full range of pathological diagnostic reagents and ancillary equipments, including liquid-based cytology, immunohistochemistry, and molecular genetic diagnosis.
Through participated with the investment of China National Pharmaceutical Group Healthcare Investment Management Co., Ltd. and Sun Yat-sen Da An Gene Co., Ltd., we are doing our best for LBP Company to become the leader of the pathological diagnosis industry in China.
We believe thatpathological diagnosis ensure promotes medical advances!